Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients
Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is…
Author Jenny A
Jenny A
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.
Making Myeloma Drugs More Targeted and Effective Using Actinium Warhead Enabling (AWE) Technology
At the recent American Association for Cancer Research (AACR) annual meeting in Chicago, Actinium Pharmaceuticals…
Myeloma 101: FISH Testing in Myeloma
FISH testing (fluorescence in situ hybridization) is a way of testing myeloma genetics in individual…
Our Next Show: Quad Treatment with Transplant for Newly Diagnosed Myeloma with Luciano Costa, MD, PhD University of Alabama
Monday, April 16, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1:00 pm…
Clinical Trial: New Takeda CD-38 Monoclonal Antibody (Subcutaneous) For Relapsed/Refractory Myeloma
A Phase I and IIa study is open to test the safety and impact on…
Researchers Suggest Increased Screening of MGUS Patients to Prevent Multiple Myeloma
Should we be screening the general population to learn more about how to prevent multiple…
Lenalidomide Every Other Day for Myeloma Patients with Kidney Concerns?
Kidney issues are a common complication for multiple myeloma patients. It can be present in…
How To Reduce Infections During Myeloma Stem Cell Transplant
Supportive care during stem cell transplant typically includes the use of strong antibiotics like ciprofloxacin…
Full Show: NAM-Natural Killer Cells with Elotuzumab by Viktoria Bachanova, MD, PhD, University of Minnesota
Viktoria Bachanova, MD, PhD University of Minnesota Interview Date: March 12, 2018 Summary Natural killer…
Clinical Trials: Isatuximab in Relapsed and Refractory Myeloma
A new CD-38 monoclonal antibody called Isatuximab (formerly known as SAR650984) is currently in Phase…
How Do I Exercise with Myeloma If I Am Elderly or Frail?
Having myeloma and corresponding treatment can weaken the body and your ability to exercise. Difficulty with…
New Drug Targeting WT1 Found to Be Effective as Post-Transplant Myeloma Therapy for High-Risk Patients
Treating high-risk multiple myeloma is a challenge and new drugs are being developed to address…
Molecule (IL-18) Helps Myeloma Hide from the Immune System and Predicts Worse Survival
Inflammation that promotes tumor growth and the ability to hide from the immune system are…
Clinical Trial: Four Drug Induction Before Transplant Using Monoclonal Antibody for Newly Diagnosed Myeloma
Myeloma experts are learning more about the power of the CD-38 targeted monoclonal antibodies and…
Increased Distress Could Influence Negative Outcomes for Myeloma Patients
Being a cancer patient is no easy task. Whether it’s financial issues, psychological burdens, or…
Patient Power: Is Sugar Part of a Myeloma-Friendly Diet?
What is the truth regarding sugar intake as a myeloma patient? Is it okay? Should…
Our Next Show: NAM-NK Cells and Elotuzumab with Veronika Bachanova, MD, PhD, Monday, March 12 @ 2:30 Central
Monday, March 12, 2018 @ 12:30 pm Pacific, 1:30 pm Mountain, 2:30 pm Central, 3:30…
Full Show: Allogeneic Transplant and Precursor Myeloma Cells with William Matsui, MD, Johns Hopkins
Dr. William Matsui, MD Johns Hopkins University Interview Date: February 16, 2018 Summary Allogeneic (or…
Spotlight on Myeloma: Multiple Myeloma Awareness Month
Amgen Oncology lit up the Southern California sky on Myeloma on Monday, March 5 in…
Clinical Trial: Study of of new BET Inhibitor Alone or In Combination for Advanced Multiple Myeloma
A new inhibtor (BET – Bromodomain and Extra-Terminal) is being tested in multiple myeloma. The…
Why I’m a Myeloma Advocate, by Jenny Ahlstrom
Our family moved to Mexico in 2009 with the vision of helping Mexican entrepreneurs create…
Patients as Partners 2018
Being “Patient Centric” is the buzz phrase in healthcare, but what does it actually mean?…
Managing Bone Disease With Multiple Myeloma
Bone disease is a common but challenging complication of multiple myeloma. More than 80% of…
What Dana Farber Researchers are Learning from the PCrowd Smoldering Myeloma and MGUS Study
The Dana Farber Center for Prevention of Progression of Blood Cancers study (PCrowd) for smoldering…
Clinical Trial: Juno Therapeutics CAR T Cell Therapy for Relapsed or Refractory Myeloma
Juno Therapeutics today opens its Phase 1/2 study to determine the safety and efficacy of JCARH125,…
Our Next Show: Safer and More Effective Allo Transplants in Myeloma and Targeting Precursor Myeloma Cells with William Matsui, MD, Johns Hopkins University, Friday, February 16 @ 2:30 Eastern
Friday, February 16, 2018 @ 11:30 am Pacific, 12:30 pm Mountain, 1:30 pm Central, 2:30…
Full Show: Dr. Martin Kaiser on Myeloma Treatment in the UK and the Study of Myeloma Genomics
Martin Kaiser, MD Institute of Cancer Research Interview Date: February 5, 2018 …
Clinical Trial: Carfilzomb, Lenalidomide and Dex for Smoldering Myeloma
More treatment options are being considered for high risk smoldering multiple myeloma patients who are…
Using Selinexor with Daratumumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
Cristina Gasparetto, MD recently shared information about a new drug combination for relapsed and refractory…
Immune System Status May Be Why Myeloma Incidence Increases With Age
A new study has found that changes to the immune system as we age may…
Clinical Trial: Daratumumab with Revlimid/Velcade/Dex for Newly Diagnosed Myeloma Patients
Revlimid, Velcade and dexamethasone (RVd) are one of the preferred induction therapies prior to transplant.…
March 24, 2018, Myeloma Crowd Round Tables: Baltimore, Maryland
Myeloma Crowd Round Tables on High-Risk Disease are day-long patient education meetings featuring world class experts…
Family Genetic Mutations Linked to Multiple Myeloma Risk
Multiple myeloma has historically not been considered an “inheritable” disease. But myeloma researchers at the…
Using Light To Eliminate Multiple Myeloma at Washington University
To hear Washington University researchers speak on this topic, register for the Myeloma Crowd Round…
The Role of the Bone Marrow Environment in MGUS or Smoldering Myeloma Progression
Dana Farber Cancer Institute myeloma specialists are studying reasons that MGUS or Smoldering Myeloma patients…
Clinical Trial: KITE CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma Opens Phase I Study
KITE Pharma, Inc. is opening a Phase I clinical trial testing its CAR T cell…
Celgene To Acquire Juno Therapeutics for CAR T Cell Myeloma Therapies
Celgene Corporation and Juno Therapeutics today announced a merger agreement in which Celgene will acquire…
My Myeloma and CAR T Cell Experience, by Daniel Riebow
Aloha to all. I live in Honolulu, HI and was diagnosed with IgG Kappa 17p…
Adding Busulfan to Melphalan for Myeloma Stem Cell Transplant Lengthens Remissions
Stem cell transplant remains the single most powerful therapy for multiple myeloma, but many patients…
Overall Survival Results for Kyprolis ASPIRE Myeloma Study Released
Kyprolis (carfizomib) is a proteasome inhibitor that is is FDA approved to be used in…
Clinical Trial: Natural Killer Cells Clinical Trial in Phase I for Relapsed and Refractory Multiple Myeloma Patients
A cellular and immune therapy company named Gamida Cell is launching a Phase I study…
Full Show: Looking to 2018 in Myeloma Care with Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center
Robert Z. Orlowski, MD MD Anderson Cancer Center Interview Date: January 5, 2018 Summary Much…
Staying On Myeloma Maintenance Therapy – How Long and Which Drug(s)?
Most myeloma patients will receive maintenance therapy as part of their treatment plan. Data has…
Myeloma 101: How Immunomodulators (IMiDs) Work in Multiple Myeloma
The story of Immunomodulatory drugs for the treatment of multiple myeloma is one of serendipity.…
C-Reactive Protein (Inflammation) Levels Before Transplant Can Indicate Overall Myeloma Survival
Mayo Clinic researchers have found a connection between c-reactive protein levels (a blood test marker…
Clinical Trial: Safer Allogeneic Transplant with Antibody to Extend Remissions
Researchers at Johns Hopkins University have been studying new methods of allogeneic transplant in order…
FDA Approves Denosumab Bone Strengthener for Myeloma Patients
Amgen’s new bone strengthener denosumab (XGEVA®) received FDA approval today for patients with multiple myeloma…
March 10, 2018, Myeloma Crowd Round Tables: St. Louis, Missouri
Myeloma Crowd Round Tables on High-Risk Disease are day-long patient education meetings featuring world class experts…
Why I Keep Moving in Spite of Myeloma by Brian Helstien
BY BRIAN HELSTIEN My parents screamed at one another right up until the divorce (when…
Clinical Trial: Daratumumab with Revlimid, Velcade and dex for Newly Diagnosed Myeloma
Revlimid, Velcade and dexamethasone (also called RVd) are considered to be an optimal treatment for…